Provided by Tiger Trade Technology Pte. Ltd.

Imunon, Inc.

1.47
+0.02001.38%
Post-market: 1.520.0480+3.27%17:56 EDT
Volume:129.35K
Turnover:189.27K
Market Cap:8.25M
PE:-0.41
High:1.53
Open:1.47
Low:1.42
Close:1.45
52wk High:5.85
52wk Low:1.39
Shares:5.61M
Float Shares:5.32M
Volume Ratio:0.53
T/O Rate:2.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5719
EPS(LYR):-6.8265
ROE:-429.72%
ROA:-77.99%
PB:4.26
PE(LYR):-0.22

Loading ...

Imunon Q1 EPS USD -0.84

THOMSON REUTERS
·
May 12

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire
·
May 12

Imunon Inc expected to post a loss of $1.11 a share - Earnings Preview

Reuters
·
May 09

Imunon schedules first-quarter results, business update conference call

Reuters
·
May 05

IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026

GlobeNewswire
·
May 05

Imunon adopts change-of-control severance agreements for top executives

Reuters
·
May 04

Imunon announces annual shareholder meeting via webcast

Reuters
·
May 04

Imunon Initiated at Buy by Maxim Group

Dow Jones
·
Apr 17

Imunon initiated with a Buy at Maxim

TIPRANKS
·
Apr 17

Analysts Offer Insights on Healthcare Companies: Imunon (IMNN), Axsome Therapeutics (AXSM) and Oric Pharmaceuticals (ORIC)

TIPRANKS
·
Apr 02

Analysts Have Conflicting Sentiments on These Healthcare Companies: Imunon (IMNN) and Novo Nordisk (NVO)

TIPRANKS
·
Apr 01

Imunon FY25 net loss narrows 22% to $14.5 million; cash climbs to $8.8 million

Reuters
·
Apr 01

BRIEF-Imunon Reports 2025 Financial Results And Provides Business Update

Reuters
·
Mar 31

Imunon Q4 EPS $(1.30) Misses $(1.13) Estimate

Benzinga Earnings
·
Mar 31

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 30

Imunon Inc expected to post a loss of $1.17 a share - Earnings Preview

Reuters
·
Mar 27

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 27

BUZZ-U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings

Reuters
·
Mar 26

Imunon announces final clinical data from OVATION 2 clinical trial

TIPRANKS
·
Mar 25

Imunon: Patients Treated With Parp Inhibitor Therapy With Imnn-001 & Standard of Care Chemotherapy Showed Median Increase in Os of 24.2 Mnths

THOMSON REUTERS
·
Mar 25